Shares of CRISPR Therapeutics AG experienced a notable surge on Thursday, climbing 11.7% to $58.15 in early afternoon trading on the Nasdaq. The stock hit an intraday high of $59.00, with approximately 2.0 million shares changing hands, bringing the company's market capitalization to nearly $5.6 billion. This uptick was part of a broader rally in the gene-editing sector, driven by positive sentiment following the company's presentation at the Jefferies Global Healthcare Conference.
The sector-wide momentum was evident as the SPDR S&P Biotech ETF gained 3.0%, with other gene-editing stocks also seeing significant gains. Intellia Therapeutics rose 14.4%, Beam Therapeutics added 10.6%, and Editas Medicine climbed 9.4%. This collective move highlights the market's renewed interest in genetic medicine, particularly after Eli Lilly's announcement of a deal worth up to $1.9 billion for rights to Ascidian Therapeutics' RNA exon-editing technology for rare inherited kidney diseases.
Eli Lilly's deal, reported by Reuters, underscores the growing demand for genetic-medicine platforms. RNA editing, which works on the temporary genetic message in cells rather than altering DNA, represents an alternative to CRISPR/Cas9 methods. Lilly CEO Michael Ehlers stated that the technology aimed to dramatically reduce the burden of genetic kidney disease, while Chief Business Officer Daniel Rosan emphasized the key advantage of not altering the patient's DNA.
CRISPR Therapeutics' main commercial asset, Casgevy, remains central to its valuation. Developed in partnership with Vertex Pharmaceuticals, Casgevy targets sickle cell disease and transfusion-dependent beta thalassemia through an ex vivo process where patient cells are edited outside the body and then returned. Vertex handles global development, manufacturing, and sales, with profits and costs split 60/40 between Vertex and CRISPR.
In the first quarter of 2026, Casgevy generated $43 million in revenue, with more than 500 patients worldwide having started treatment. Chairman and CEO Samarth Kulkarni called 2026 a defining year for the company, emphasizing the importance of upcoming clinical updates. Beyond Casgevy, investors are focused on the in vivo pipeline, including CTX310 in a Phase 1b study for lipid disorders, and second-half readouts for zugo-cel, an off-the-shelf cell therapy for autoimmune diseases and blood cancers.
Despite the rally, the stock carries typical biotech risks. CRISPR Therapeutics reported a net loss of $122.9 million for the first quarter, and the company cautions that its experimental therapies may never complete trials or receive regulatory approval. If Casgevy demand lags, trial results disappoint, or investor appetite for loss-making biotech wanes, the recent gains could reverse quickly.
Looking ahead, the stock's performance may hinge on gene-editing sentiment, updates on Casgevy sales, and management's commentary on clinical readouts expected in 2026. With no immediate approval or pivotal trial results on the horizon, price action is likely to remain tied to sector trends and investor sentiment.
